Yılmaz Mukaddes, Erdiş Eda, Uçar Mahmut, Yücel Birsen
Sivas Cumhuriyet University Faculty of Medicine, Department of Medical Oncology, Sivas, Turkey.
Sivas Cumhuriyet University Faculty of Medicine, Department of Radiation Oncology, Sivas, Turkey.
Breast Care (Basel). 2025 Mar 3;20(1):27-39. doi: 10.1159/000543304. Epub 2025 Jan 4.
The present study evaluated the prognostic significance of panimmune-inflammation value (PIV) and PILE (a composite score of PIV, lactate dehydrogenase [LDH], and Eastern Cooperative Oncology Group Performance Status [ECOG PS]) in patients with non-metastatic luminal A breast cancer.
Non-metastatic stage (I-III) luminal A breast cancer patients who were admitted to Cumhuriyet University Oncology Center were retrospectively examined. The PIV score was calculated using the neutrophil, platelet, monocyte, and lymphocyte counts at the time of diagnosis. The PIV, LDH, and ECOG PS parameters were used for the PILE score.
A total of 293 patients were included. The median PIV was 254.89; 239 (82%) patients had low PILE score; and 54 (18%) patients had high PILE score. Patients with low PIV and low PILE scores had significantly better OS and disease-free survival (DFS) (PIV; = 0.033 for OS and = 0.024 for DFS and PILE; = 0.001 for OS and = 0.005 for DFS). The PIV and PILE scores were found to be significant prognostic factors associated with OS and DFS. The PIV score was found to be an independent prognostic factor for OS and DFS (OS: score 0 vs. 1; HR: 1.89, 95% CI: 1.06-3.35; = 0.029; and DFS: score 0 vs. 1; HR: 1.75, 95% CI: 1.01-3.01; = 0.044). The PILE score was not an independent prognostic factor associated with OS or DFS.
Survival was better in those with lower PIV and PILE scores. The PIV score was an independent prognostic factor for survival in these patients.
本研究评估了全免疫炎症值（PIV）和PILE（PIV、乳酸脱氢酶[LDH]及东部肿瘤协作组体能状态[ECOG PS]的综合评分）在非转移性腔面A型乳腺癌患者中的预后意义。
对 Cumhuriyet大学肿瘤中心收治的非转移性（I - III期）腔面A型乳腺癌患者进行回顾性研究。PIV评分通过诊断时的中性粒细胞、血小板、单核细胞及淋巴细胞计数计算得出。PIV、LDH及ECOG PS参数用于计算PILE评分。
共纳入293例患者。PIV中位数为254.89；239例（82%）患者PILE评分低；54例（18%）患者PILE评分高。PIV和PILE评分低的患者总生存期（OS）和无病生存期（DFS）明显更好（PIV：OS为0.033，DFS为0.024；PILE：OS为0.001，DFS为0.005）。PIV和PILE评分是与OS和DFS相关的显著预后因素。PIV评分是OS和DFS的独立预后因素（OS：评分0与1相比；HR：1.89，95%CI：1.06 - 3.35；P = 0.029；DFS：评分0与1相比；HR：1.75，95%CI：1.01 - 3.01；P = 0.044）。PILE评分不是与OS或DFS相关的独立预后因素。
PIV和PILE评分较低者生存情况更好。PIV评分是这些患者生存的独立预后因素。
